Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
about
Nanoparticles - known and unknown health risksEudragit S100 entrapped insulin microspheres for oral delivery.Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ)Inhaled insulin--a new therapeutic option in the treatment of diabetes mellitus.Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetesCarrier-based strategies for targeting protein and peptide drugs to the lungs.The effect of exercise on the absorption of inhaled human insulin in healthy volunteers.Inhaled insulin delivery--where are we now?First approved inhaled insulin therapy for diabetes mellitus.Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.Evaluation of novel particles as pulmonary delivery systems for insulin in rats.Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes.Inspiratory efforts achieved in use of the Technosphere insulin inhalation system.Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes.A review of inhaled technosphere insulin.Novel non-invasive methods of insulin delivery.Insulin therapies: Current and future trends at dawn.AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.Technosphere insulin: defining the role of Technosphere particles at the cellular level.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Can inhaled insulin be used for the treatment of diabetes mellitus?Insulin induces airway smooth muscle contractionPulmonary delivery of anorectic oxyntomodulin in rats: food intake suppression, reduced body weight gain and pharmacokinetics.Population pharmacokinetic model of human insulin following different routes of administration.Effect of matrix composition, sphere size and hormone concentration on diffusion coefficient of insulin for controlled gastrointestinal delivery for diabetes treatment.Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism.Insulin loaded eudragit L100 microspheres for oral delivery: preliminary in vitro studies.
P2860
Q24557518-86173347-9F49-4DA3-93E9-4E14D989731EQ33229455-FEF0E3A3-9ED6-4A81-9EE9-AE65BAE8C243Q33797394-490FC117-5D87-4B89-A47F-CDBCEC77AA17Q35058109-C1EF6C5B-0D22-4DA5-8D9E-DCEDF4B8489DQ35876380-87548E79-DD01-42F7-934C-765EA24FA2A8Q36250762-1ADFA545-90B0-4B9E-89F3-F7608FAC1C82Q36535857-60F75834-70DD-4BC9-A659-D2D9852D5D27Q36616573-A6F920E2-21A0-4A1C-8859-57FE4E91A6C5Q36690218-E662DAFA-7731-46D3-BFD1-05D2AD6D9D6CQ36945312-D8C329BB-9CFB-47D3-8862-4F6B379F4440Q37362017-BF486D6B-5165-4ED7-BE62-A581AD158C91Q37404094-692B797A-FD61-42BC-9E22-434567194346Q37404452-224FFFA3-0A89-4BEE-8A33-277CBEA6E38EQ37407977-5D3EFC46-57DE-4BB7-85AC-43E63DA1D255Q37762086-433F9CE4-3F5A-4018-BF07-2C3C423B0CD8Q38055517-2875BD04-38D6-4741-B7D1-583817622140Q38089594-F11335C9-C5B9-4921-BF57-72F2932CCA88Q38589120-55929EF7-DD59-4282-9873-0CD592DA9FA5Q39741788-E20AF3D4-A408-4262-82BC-8BFD74678363Q42008289-B605D879-93C9-432F-824C-ECE35EAEBD1BQ42472493-ADA73160-58F3-41E2-AA35-57D1194D759FQ42605880-0899027E-EB5C-4625-A554-4FC5618A3486Q45011996-FA20FE4A-E0CD-4625-A2F2-D4D7B2B9A071Q45981512-151BFD28-B515-4DAA-99D1-C0EC7E1BFB86Q47175658-CA4530AF-ACA0-4BC8-8A5F-2CABF832D571Q47688994-9AF7A3AA-82F4-4A58-A3DB-09B99B46D65FQ51280152-1AAF6B94-28B0-4C4B-B100-74CBEA5A0C45
P2860
Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@en
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@nl
type
label
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@en
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@nl
prefLabel
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@en
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@nl
P2093
P356
P1476
Technosphere/Insulin--proof of ...... lation for pulmonary delivery.
@en
P2093
P356
10.1055/S-2002-19989
P577
2002-01-01T00:00:00Z